Base de dados : MEDLINE
Pesquisa : D10.251.355.255.550.400.200 [Categoria DeCS]
Referências encontradas : 10810 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1081 ir para página                         

  1 / 10810 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29482802
[Au] Autor:Huang X; Chen L; Xia YB; Xie M; Sun Q; Yao B
[Ad] Endereço:Reproductive Medical Center, Jinling Hospital Affiliated to Medical School of Nanjing University, Nanjing 210002, China.
[Ti] Título:Effects of electroacupuncture on luteal regression and steroidogenesis in ovarian hyperstimulation syndrome model rat.
[So] Source:Life Sci;197:1-9, 2018 Mar 15.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: Electroacupuncture (EA) is an effective and safe therapeutic method widely used for treating clinical diseases. Previously, we found that EA could decrease serum hormones and reduce ovarian size in ovarian hyperstimulation syndrome (OHSS) rat model. Nevertheless, the mechanisms that contribute to these improvements remain unclear. MATERIALS AND METHODS: HE staining was used to count the number of corpora lutea (CL) and follicles. Immunohistochemical and ELISA were applied to examine luteal functional and structural regression. Immunoprecipitation was used for analyzing the interaction between NPY (neuropeptide Y) and COX-2; western blotting and qRT-PCR were used to evaluate the expressions of steroidogenic enzymes and PKA/CREB pathway. KEY FINDINGS: EA treatment significantly reduced the ovarian weight and the number of CL, also decreased ovarian and serum levels of PGE2 and COX-2 expression; increased ovarian PGF2α levels and PGF2α/PGE2 ratio; decreased PCNA expression and distribution; and increased cyclin regulatory inhibitor p27 expression to have further effect on the luteal formation, and promote luteal functional and structural regression. Moreover, expression of COX-2 in ovaries was possessed interactivity increased expression of NPY. Furthermore, EA treatment lowered the serum hormone levels, inhibited PKA/CREB pathway and decreased the expressions of steroidogenic enzymes. Hence, interaction with COX-2, NPY may affect the levels of PGF2α and PGE2 as well as impact the proliferation of granulosa cells in ovaries, thus further reducing the luteal formation, and promoting luteal structural and functional regression, as well as the ovarian steroidogenesis following EA treatment. SIGNIFICANCE: EA treatment could be an option for preventing OHSS in ART.
[Mh] Termos MeSH primário: Corpo Lúteo
Dinoprosta/metabolismo
Dinoprostona/biossíntese
Eletroacupuntura
Síndrome de Hiperestimulação Ovariana
[Mh] Termos MeSH secundário: Animais
Corpo Lúteo/metabolismo
Corpo Lúteo/patologia
Ciclo-Oxigenase 2/biossíntese
Modelos Animais de Doenças
Feminino
Regulação da Expressão Gênica
Síndrome de Hiperestimulação Ovariana/metabolismo
Síndrome de Hiperestimulação Ovariana/patologia
Síndrome de Hiperestimulação Ovariana/terapia
Antígeno Nuclear de Célula em Proliferação/biossíntese
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Proliferating Cell Nuclear Antigen); B7IN85G1HY (Dinoprost); EC 1.14.99.1 (Cyclooxygenase 2); EC 1.14.99.1 (Ptgs2 protein, rat); K7Q1JQR04M (Dinoprostone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180228
[St] Status:MEDLINE


  2 / 10810 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28458346
[Au] Autor:Ohyama K; Kawakami H; Inoue M
[Ad] Endereço:Education Center for Experiential Pharmacy Practice, School of Pharmacy, Tokyo University of Pharmacy and Life Science.
[Ti] Título:Blood Pressure Elevation Associated with Topical Prostaglandin F2α Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases.
[So] Source:Biol Pharm Bull;40(5):616-620, 2017.
[Is] ISSN:1347-5215
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Topical prostaglandin F2α (PGF2α) analogs are widely used as the first line of therapy for glaucoma. Systemic PGF2α is suggested to increase blood pressure. Some ophthalmic formulations with ß-receptor blocking or α-receptor stimulating actions are reported to cause systemic adverse events such as a decrease in heart rate and blood pressure. The objective of this study was to evaluate the association between topical PGF2α analogs and blood pressure elevation. We analyzed the reports obtained from the Food and Drug Administration Adverse Event Reporting System (FAERS) database from the first quarter of 2004 until the end of 2015 and the Japanese Adverse Drug Event Report (JADER) database from April 2004 to January 2016 for signal detection using reporting odds ratio (ROR), a method of disproportionality analyses. Signals are considered significant if the ROR estimates and lower bound of the 95% confidence interval (CI) exceed 1. Preferred terms in the Medical Dictionary for Regulatory Activities were utilized to define blood pressure elevation. A total of 6156081 reports from the FAERS and 351226 reports from the JADER were analyzed. The significant RORs with 95% CI were calculated to be 1.82 (95% CI: 1.55-2.13) for bimatoprost, 1.69 (95% CI: 1.53-1.85) for latanoprost, and 2.17 (95% CI: 1.82-2.59) for travoprost from the FAERS. From the JADER, 5.01 (95% CI: 1.59-15.8) was calculated for bimatoprost and 8.02 (95% CI: 2.94-21.9) for tafluprost. The resulting data suggest the necessity for further clinical research on blood pressure elevation associated with topical PGF2α analogs and close monitoring.
[Mh] Termos MeSH primário: Pressão Sanguínea/efeitos dos fármacos
Dinoprosta/análogos & derivados
Dinoprosta/efeitos adversos
Hipertensão/induzido quimicamente
[Mh] Termos MeSH secundário: Administração Tópica
Sistemas de Notificação de Reações Adversas a Medicamentos
Bases de Dados Factuais
Dinoprosta/administração & dosagem
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
Seres Humanos
Hipertensão/epidemiologia
Incidência
Japão/epidemiologia
Razão de Chances
Estados Unidos/epidemiologia
United States Food and Drug Administration
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
B7IN85G1HY (Dinoprost)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1248/bpb.b16-00848


  3 / 10810 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28743542
[Au] Autor:Maia J; Almada M; Silva A; Correia-da-Silva G; Teixeira N; Sá SI; Fonseca BM
[Ad] Endereço:UCIBIO, REQUIMTE, Departamento de Ciências Biológicas, Laboratório de Bioquímica, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal.
[Ti] Título:The endocannabinoid system expression in the female reproductive tract is modulated by estrogen.
[So] Source:J Steroid Biochem Mol Biol;174:40-47, 2017 11.
[Is] ISSN:1879-1220
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The endocannabinoid system (ECS) is involved in several physiological events that resulted in a growing interest in its modulation. Moreover, the uterine levels of anandamide (AEA), the major endocannabinoid, must be tightly regulated to create proper embryo implantation conditions. However, there are no evidences about the regulation of AEA in uterus by estrogen. Thus, the aim of this study is to elucidate whether estradiol benzoate (EB) and tamoxifen (TAM) administration to ovariectomized (OVX) rats can induce changes in the expression of cannabinoid receptors and AEA-metabolic enzymes in uterus by evaluating gene transcription and protein levels by qPCR, Western blot and immunohistochemistry. Moreover, the plasmatic and uterine levels of AEA and of prostaglandin E (PGE ) and prostaglandin F α (PGF ), the major cyclooxygenase-2 (COX-2) products, were determined by UPLC-MS/MS. The immunohistochemistry showed that cannabinoid receptors, as well as AEA-metabolic enzymes are mainly located in the epithelial cells of both lumen and glands and, to a lesser extent, in the muscle cells. Moreover, EB administration to OVX rats significantly increased CB1, CB2, NAPE-PLD, FAAH and COX-2 expression and transcription. These effects were absent in TAM and TAM+EB treatments showing that this response is estrogen receptor dependent. Additionally, although uterine levels of AEA remained unchanged in EB or TAM treated animals, they showed a rise with EB treatment in plasma. The latter also produced a decrease in uterine PGE levels. In summary, these data collectively indicate that the expression of ECS components, as well as, the AEA and PGE levels in rat uterus is modulated by EB. Thus, estradiol may have a direct regulatory role in the modulation of ECS in female reproductive tissues.
[Mh] Termos MeSH primário: Estradiol/análogos & derivados
Estrogênios/farmacologia
Tamoxifeno/farmacologia
Útero/efeitos dos fármacos
[Mh] Termos MeSH secundário: Amidoidrolases/genética
Amidoidrolases/metabolismo
Animais
Ácidos Araquidônicos/sangue
Ácidos Araquidônicos/metabolismo
Ciclo-Oxigenase 2/genética
Ciclo-Oxigenase 2/metabolismo
Dinoprosta/sangue
Dinoprostona/sangue
Dinoprostona/metabolismo
Endocanabinoides/sangue
Endocanabinoides/metabolismo
Estradiol/farmacologia
Feminino
Tamanho do Órgão/efeitos dos fármacos
Ovariectomia
Fosfolipase D/genética
Fosfolipase D/metabolismo
Alcamidas Poli-Insaturadas/sangue
Alcamidas Poli-Insaturadas/metabolismo
Ratos Wistar
Receptor CB1 de Canabinoide/genética
Receptor CB1 de Canabinoide/metabolismo
Receptor CB2 de Canabinoide/genética
Receptor CB2 de Canabinoide/metabolismo
Útero/metabolismo
Útero/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Arachidonic Acids); 0 (Endocannabinoids); 0 (Estrogens); 0 (Polyunsaturated Alkamides); 0 (Receptor, Cannabinoid, CB1); 0 (Receptor, Cannabinoid, CB2); 094ZI81Y45 (Tamoxifen); 1S4CJB5ZGN (estradiol 3-benzoate); 4TI98Z838E (Estradiol); B7IN85G1HY (Dinoprost); EC 1.14.99.1 (Cyclooxygenase 2); EC 1.14.99.1 (Ptgs2 protein, rat); EC 3.1.4.4 (NAPE-PLD protein, rat); EC 3.1.4.4 (Phospholipase D); EC 3.5.- (Amidohydrolases); EC 3.5.1.- (fatty-acid amide hydrolase); K7Q1JQR04M (Dinoprostone); UR5G69TJKH (anandamide)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171208
[Lr] Data última revisão:
171208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE


  4 / 10810 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29017959
[Au] Autor:Elfsmark L; Ågren L; Akfur C; Bucht A; Jonasson S
[Ad] Endereço:Swedish Defence Research Agency, CBRN Defence and Security, Umeå, Sweden. Electronic address: linda.elfsmark@foi.se.
[Ti] Título:8-Isoprostane is an early biomarker for oxidative stress in chlorine-induced acute lung injury.
[So] Source:Toxicol Lett;282:1-7, 2018 Jan 05.
[Is] ISSN:1879-3169
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Inhalation of chlorine (Cl ) may cause oxidative acute lung injury (ALI) characterized by pulmonary edema, pneumonitis, and hyperreactive airways. The aim of the study was to identify possible biomarkers for Cl -induced ALI. Female BALB/c mice were exposed to Cl for 15min using two protocols 1) concentration-dependent response (25-200ppm) and 2) time-kinetics (2h-14days post-exposure). Exposure to 50-200ppm Cl caused a concentration-dependent inflammatory response with increased expression of IL-1ß, IL-6 and CXCL1/KC in bronchoalveolar lavage fluid 2-6h after exposure which was followed by increased lung permeability and a neutrophilic inflammation 12-24h post-exposure. The early inflammatory cytokine response was associated with a clear but transient increase of 8-isoprostane, a biomarker for oxidative stress, with its maximum at 2h after exposure. An increase of 8-isoprostane could also be detected in serum 2h after exposure to 200ppm Cl , which was followed by increased levels of IL-6 and CXCL1/KC and signs of increased fibrinogen and PAI-1. Melphalan, a non-oxidizing mustard gas analog, did not increase the 8-isoprostane levels, indicating that 8-isoprostane is induced in airways through direct oxidation by Cl . We conclude that 8-isoprostane represents an early biomarker for oxidative stress in airways and in the blood circulation following Cl -exposure.
[Mh] Termos MeSH primário: Lesão Pulmonar Aguda/sangue
Cloro/toxicidade
Dinoprosta/análogos & derivados
Estresse Oxidativo/efeitos dos fármacos
[Mh] Termos MeSH secundário: Lesão Pulmonar Aguda/induzido quimicamente
Lesão Pulmonar Aguda/imunologia
Animais
Biomarcadores/sangue
Líquido da Lavagem Broncoalveolar/química
Dinoprosta/sangue
Relação Dose-Resposta a Droga
Feminino
Exposição por Inalação
Camundongos Endogâmicos BALB C
Surfactantes Pulmonares/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Pulmonary Surfactants); 27415-26-5 (8-epi-prostaglandin F2alpha); 4R7X1O2820 (Chlorine); B7IN85G1HY (Dinoprost)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171012
[St] Status:MEDLINE


  5 / 10810 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771115
[Au] Autor:Abel JM; Bishop BE; Thomas JM; Ellersieck MR; Poock SE; Smith MF; Patterson DJ
[Ad] Endereço:Division of Animal Sciences, University of Missouri, Columbia, Missouri, USA; College of Veterinary Medicine, University of Missouri, Columbia, Missouri, USA.
[Ti] Título:Comparing strategies to synchronize estrus before fixed-time artificial insemination in primiparous 2-year-old beef cows.
[So] Source:Theriogenology;87:306-315, 2017 Jan 01.
[Is] ISSN:1879-3231
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Two experiments evaluated controlled internal drug release (CIDR)-based protocols to synchronize estrus in primiparous 2-year-old beef cows. In each experiment, treatments were balanced according to body condition score and days postpartum. Experiment 1 compared the 14-day CIDR-PG (14-d) and 7-day CO-Synch + CIDR (7-d) protocols on the basis of estrous response, pregnancy rates after fixed-time artificial insemination (FTAI), and final pregnancy rate. Cows assigned to 14-d (n = 355) received a CIDR insert on Day 0 with removal on Day 14. Cows assigned to 7-d (n = 349) received gonadotropin releasing hormone (GnRH) and a CIDR insert on Day 23. On Day 30, CIDRs were removed from 7-d cows, and PGF was administered to all cows in each treatment. On Day 33, GnRH was administered concurrent with FTAI at 66 and 72 hours after PGF for 7-d and 14-d treated cows, respectively. Estrous response before FTAI was higher for 7-d compared with 14-d cows (74% vs. 43%, respectively; P < 0.0001); however, pregnancy rates resulting from FTAI were similar (14-d 63%; 7-d 64%; P = 0.52). Ovarian follicular dynamics and serum estradiol-17ß concentrations were evaluated among a subset of cows assigned to each protocol. Dominant follicle diameter was smaller at PGF (P = 0.04) and FTAI (P = 0.002) among 14-d cows compared with 7-d cows; however, estradiol-17ß at PGF (P = 0.06) and FTAI (P = 0.001) was greater for 14-d versus 7-d treated cows. Experiment 2 compared estrous response and pregnancy rates in 2-year-old beef cows after FTAI- or split-time artificial insemination (STAI) following synchronization of estrus with the 14-day protocol. Cows assigned to FTAI (n = 266) were inseminated at a fixed time concurrent with GnRH at 72 hours after PGF regardless of estrus expression, whereas cows assigned to STAI (n = 257) were inseminated based on estrus expression as determined by activation of an estrus detection aid. Cows assigned to STAI that exhibited estrus by 72 hours were inseminated; however, AI was delayed until 24 hours after GnRH (96 hours after PGF ) for nonestrous cows. Total estrous response was increased for STAI- versus FTAI-treated cows (STAI 64%; FTAI 42%; P < 0.0001); pregnancy rates resulting from AI were similar (STAI 55%; FTAI 56%; P = 0.60). In summary, the 14-day CIDR-PG and 7-day CO-Synch + CIDR protocols can be used effectively to synchronize estrus before FTAI in primiparous 2-year-old beef cows. Although expression of estrus was increased using STAI in conjunction with the 14-day protocol, this approach did not increase pregnancy rates compared with FTAI.
[Mh] Termos MeSH primário: Bovinos
Sincronização do Estro/métodos
Inseminação Artificial/veterinária
[Mh] Termos MeSH secundário: Administração Intravaginal
Animais
Dinoprosta/administração & dosagem
Dinoprosta/farmacologia
Esquema de Medicação
Estradiol/sangue
Feminino
Folículo Ovariano/diagnóstico por imagem
Folículo Ovariano/efeitos dos fármacos
Paridade
Gravidez
Progesterona/administração & dosagem
Progesterona/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
4G7DS2Q64Y (Progesterone); 4TI98Z838E (Estradiol); B7IN85G1HY (Dinoprost)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171201
[Lr] Data última revisão:
171201
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  6 / 10810 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28964662
[Au] Autor:Desideri G; Bocale R; D'Amore A; Necozione S; Boscherini M; Carnassale G; Barini A; Barini A; Bellantone R; Lombardi CP
[Ad] Endereço:Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy. Electronic address: giovambattista.desideri@univaq.it.
[Ti] Título:Replacement therapy with levothyroxine modulates platelet activation in recent-onset post-thyroidectomy subclinical hypothyroidism.
[So] Source:Nutr Metab Cardiovasc Dis;27(10):896-901, 2017 Oct.
[Is] ISSN:1590-3729
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND AIM: Subclinical hypothyroidism has been linked to increased risk of atherosclerotic disease. Soluble CD40 ligand (sCD40L), mainly derived from activated platelets, and the lipid peroxidation product 8-iso-prostaglandin F (8-iso-PGF ) are known to play a relevant pathophysiological role in atherogenesis. In this study, we analyzed the relationship between thyroid hormones and circulating levels of sCD40L and 8-iso-PGF in patient with recent-onset post-thyroidectomy subclinical hypothyroidism under replacement therapy. METHODS AND RESULTS: Circulating levels of thyroid hormones, sCD40L, and 8-iso-PGF were assessed in 40 recently thyroidectomized patients (33 females, mean age 52.0 ± 11.7 years) at baseline (5-7 day after surgery) and after 2 months under replacement therapy with levothyroxine (LT-4). At baseline, circulating levels of thyroid hormones were indicative of a subclinical hypothyroidism (TSH 7.7 ± 3.9 µU/mL, FT3 1.8 ± 0.6 pg/mL, and FT3 8.9 ± 3.0 pg/mL). Circulating levels of sCD40L and 8-iso-PGF were directly correlated with each other (r = 0.360, p = 0.023) and with TSH levels (r = 0.322, p = 0.043 and r = 0.329 p = 0.038, respectively). After 2 months under the replacement therapy with LT-4 circulating levels of TSH (from 7.7 ± 3.9 to 2.7 ± 2.8 µU/mL, p < 0.0001), sCD40L (from 6.11 ± 2.41 to 2.43 ± 2.00 ng/mL, p < 0.0001) and 8-iso-PGF (from 45.33 ± 6.94 to 40.36 ± 6.20, p < 0.0001) significantly decreased. Changes in circulating levels of sCD40L and 8-iso-PGF were directly correlated with each other (r = 0.349 p = 0.028) and with changes in TSH levels (r = 0.367 p = 0.020 and r = 0.339 p = 0.032, respectively). CONCLUSION: Our study suggests an influential role of TSH on proatherogenic activation of platelets, probably through enhanced lipid peroxidation. These findings could partially explain the increased susceptibility of patients with subclinical hypothyroidism to develop atherosclerotic disease.
[Mh] Termos MeSH primário: Plaquetas/efeitos dos fármacos
Terapia de Reposição Hormonal
Hipotireoidismo/tratamento farmacológico
Ativação Plaquetária/efeitos dos fármacos
Tireoidectomia/efeitos adversos
Tiroxina/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Doenças Assintomáticas
Biomarcadores/sangue
Plaquetas/metabolismo
Ligante de CD40/sangue
Dinoprosta/análogos & derivados
Dinoprosta/sangue
Feminino
Seres Humanos
Hipotireoidismo/sangue
Hipotireoidismo/diagnóstico
Hipotireoidismo/etiologia
Peroxidação de Lipídeos/efeitos dos fármacos
Masculino
Meia-Idade
Tireotropina/sangue
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers); 147205-72-9 (CD40 Ligand); 27415-26-5 (8-epi-prostaglandin F2alpha); 9002-71-5 (Thyrotropin); B7IN85G1HY (Dinoprost); Q51BO43MG4 (Thyroxine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171002
[St] Status:MEDLINE


  7 / 10810 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28886988
[Au] Autor:El-Bassossy HM; Awan Z; El-Mas MM
[Ad] Endereço:Department of Pharmacology, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; Department of Pharmacology, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt. Electronic address: helbassossy@kau.edu.sa.
[Ti] Título:Perinatal ciclosporin A exposure elicits sex-related cardiac dysfunction and inflammation in the rat progeny.
[So] Source:Toxicol Lett;281:35-43, 2017 Nov 05.
[Is] ISSN:1879-3169
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Ciclosporin A (CSA) has been identified with harmful cardiotoxicity but little, if any, is known about the influence of perinatal exposure upon the cardiac function of the progeny. The present work examines the premise that perinatal contact with CSA undermines the cardiac function of sexually mature rats. Administration of CSA (15mg/kg/day sc) to pregnant rats from day 6 of conception till weaning led to a decrease in gradient of the end-systolic pressure-volume relationship by a factor of ten for male progeny and a factor of two for female progeny. Perinatally CSA-exposed male, but not female, progeny also demonstrated significantly increased systolic and diastolic blood pressure, along with significantly increased JT interval and a tendency towards increased QTc interval, indicating delayed left ventricular (LV) repolarization and perhaps arrhythmogenesis. Conversely, female, but not male, progeny exposed perinatally to CSA showed a delay in atrioventricular (AV) conduction, as demonstrated by significantly prolonged P duration and a tendency towards increased PR interval. CSA increased serum tumor necrosis factor α (TNFα) and decreased serum adiponectin levels and cardiac adiponectin receptor expression in male progeny, in contrast to no effects in female progeny. Signs of improved oxidative state (decreased 8-isoprostane and increased catalase activity) appeared only in CSA-exposed female rats. Moreover, cardiac muscle degeneration and pyknosis was more observed in male than in female rats. In brief, the sex plays a key role in determining the extent of the deterioration in functional and inflammatory states of the heart that follow perinatal CSA exposure in rats.
[Mh] Termos MeSH primário: Ciclosporina/toxicidade
Insuficiência Cardíaca/diagnóstico
Inflamação/diagnóstico
Fatores Sexuais
[Mh] Termos MeSH secundário: Adiponectina/sangue
Animais
Animais Recém-Nascidos
Catalase/sangue
Dinoprosta/análogos & derivados
Dinoprosta/sangue
Eletrocardiografia
Feminino
Insuficiência Cardíaca/induzido quimicamente
Ventrículos do Coração/efeitos dos fármacos
Ventrículos do Coração/metabolismo
Hemodinâmica/efeitos dos fármacos
Inflamação/induzido quimicamente
Masculino
Estresse Oxidativo/efeitos dos fármacos
Assistência Perinatal
Ratos
Ratos Wistar
Fator de Necrose Tumoral alfa/sangue
Função Ventricular Esquerda/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adiponectin); 0 (Tumor Necrosis Factor-alpha); 27415-26-5 (8-epi-prostaglandin F2alpha); 83HN0GTJ6D (Cyclosporine); B7IN85G1HY (Dinoprost); EC 1.11.1.6 (Catalase)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171106
[Lr] Data última revisão:
171106
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170910
[St] Status:MEDLINE


  8 / 10810 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28800645
[Au] Autor:Lee Y; Choo J; Kim SJ; Heo G; Pothoulakis C; Kim YH; Im E
[Ad] Endereço:College of Pharmacy, Pusan National University, Busan, Republic of Korea.
[Ti] Título:Analysis of endogenous lipids during intestinal wound healing.
[So] Source:PLoS One;12(8):e0183028, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Intestinal wound healing is a new therapeutic goal for inflammatory bowel disease (IBD) as complete healing of the mucosa is the key element of clinical remission in IBD. Previous studies showed that termination of inflammation can be achieved by adding pro-resolving lipids like DHA and EPA exogenously. However, the roles of these lipids in mucosal healing have not been investigated. To recapitulate intestinal healing process, mice were received dextran sodium sulfate (DSS) for 7 days in the drinking water followed by regular tap water for 5 additional days. DSS-induced intestinal inflammation featuring body weight loss, histological tissue damage, increased cytokine production and infiltration of inflammatory cells was gradually reduced upon switching to water. To investigate whether endogenous lipids play a role in mucosal healing, the lipidomics analysis of mouse serum was performed. Reduced levels of arachidonic acid, the biosynthetic precursor of prostaglandin F (PGF)2α, 19H-PGF1α, the metabolite of prostacyclin, and 20H-PGF2α, the metabolite of PGF2α, suggest subsiding inflammation. In contrast, increased levels of an active metabolite of resolvin D1 along with decreased levels of its precursor DHA as well as decreased levels of the precursor of resolvin E, 18-hydroxy-eicosapentaenoic acid, suggest inauguration of mucosal healing by endogenous lipids. Furthermore, exogenously supplied fish oil enhanced the process even further. These results suggest the presence of mucosal healing regulated by endogenous pro-healing lipids and also indicate that the remission state of IBD could be prolonged by enhancing the levels of these lipids.
[Mh] Termos MeSH primário: Colite/sangue
Colo/efeitos dos fármacos
Ácidos Docosa-Hexaenoicos/sangue
Ácido Eicosapentaenoico/sangue
Metabolismo dos Lipídeos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Ácido Araquidônico/sangue
Colite/induzido quimicamente
Colite/dietoterapia
Colite/patologia
Colo/metabolismo
Colo/patologia
Sulfato de Dextrana
Dinoprosta/sangue
Modelos Animais de Doenças
Ácidos Docosa-Hexaenoicos/administração & dosagem
Ácido Eicosapentaenoico/administração & dosagem
Ácido Eicosapentaenoico/análogos & derivados
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Recuperação de Função Fisiológica/efeitos dos fármacos
Remissão Espontânea
Perda de Peso
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid); 0 (resolvin D1); 25167-62-8 (Docosahexaenoic Acids); 27YG812J1I (Arachidonic Acid); 9042-14-2 (Dextran Sulfate); AAN7QOV9EA (Eicosapentaenoic Acid); B7IN85G1HY (Dinoprost)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170812
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183028


  9 / 10810 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28714741
[Au] Autor:Kim G; Oh S; Jin SM; Hur KY; Kim JH; Lee MK
[Ad] Endereço:a Division of Endocrinology and Metabolism, Department of Medicine , Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , Republic of Korea.
[Ti] Título:The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
[So] Source:Expert Opin Pharmacother;18(12):1179-1186, 2017 Aug.
[Is] ISSN:1744-7666
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To compare the effects of either vildagliptin or glimepiride on glycemic variability, oxidative stress, and endothelial parameters in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin alone. METHODS: In this randomized, open-label, parallel study, 34 patients with T2DM being treated with metformin having an HbA1c of 7.0-10.0% were allocated into either the vildagliptin or glimepiride group. A mixed-meal tolerance test and 72-hour continuous glucose monitoring were conducted, and urinary 8-iso-prostaglandinF (PGF ) and endothelial-dependent flow-mediated dilatation (FMD) were evaluated at baseline and after 12 weeks of treatment. RESULTS: Similar significant improvements in HbA1c level were shown in both vildagliptin (-0.8%) and glimepiride (-0.9%) groups after treatment (Ps<0.001). The mean amplitude of glycemic excursions (MAGE) and the mean of daily differences (MODD) were significantly decreased by vildagliptin (P = 0.044 and P = 0.031, respectively) but not by glimepiride. Glimepiride was significantly associated with a higher incidence of hypoglycemia than vildagliptin (P = 0.005). There were no significant differences in urinary 8-iso-PGF or FMD between the two groups. CONCLUSIONS: Vildagliptin effectively improved glucose level with a significantly greater reduction in glycemic variability and hypoglycemia than glimepiride in patients with T2DM ongoing metformin therapy. The two drugs showed no significant differences in urinary 8-iso-PGF and FMD. TRIAL REGISTRATION: NCT01404676.
[Mh] Termos MeSH primário: Adamantano/análogos & derivados
Diabetes Mellitus Tipo 2/tratamento farmacológico
Hipoglicemiantes/uso terapêutico
Metformina/uso terapêutico
Nitrilos/uso terapêutico
Pirrolidinas/uso terapêutico
Compostos de Sulfonilureia/uso terapêutico
[Mh] Termos MeSH secundário: Adamantano/administração & dosagem
Adamantano/efeitos adversos
Adamantano/uso terapêutico
Glicemia/efeitos dos fármacos
Dinoprosta/análogos & derivados
Dinoprosta/urina
Quimioterapia Combinada
Feminino
Hemoglobina A Glicada/análise
Seres Humanos
Hipoglicemia/induzido quimicamente
Hipoglicemiantes/administração & dosagem
Hipoglicemiantes/efeitos adversos
Masculino
Metformina/administração & dosagem
Metformina/efeitos adversos
Meia-Idade
Nitrilos/administração & dosagem
Nitrilos/efeitos adversos
Pirrolidinas/administração & dosagem
Pirrolidinas/efeitos adversos
Compostos de Sulfonilureia/administração & dosagem
Compostos de Sulfonilureia/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Glycated Hemoglobin A); 0 (Hypoglycemic Agents); 0 (Nitriles); 0 (Pyrrolidines); 0 (Sulfonylurea Compounds); 0 (hemoglobin A1c protein, human); 27415-26-5 (8-epi-prostaglandin F2alpha); 6KY687524K (glimepiride); 9100L32L2N (Metformin); B7IN85G1HY (Dinoprost); I6B4B2U96P (vildagliptin); PJY633525U (Adamantane)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170718
[St] Status:MEDLINE
[do] DOI:10.1080/14656566.2017.1353080


  10 / 10810 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28542188
[Au] Autor:Fujita K; Tokuda H; Kuroyanagi G; Yamamoto N; Kainuma S; Kawabata T; Sakai G; Matsushima-Nishiwaki R; Kozawa O; Otsuka T
[Ad] Endereço:Department of Orthopedic Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
[Ti] Título:HSP90 inhibitors potentiate PGF2α-induced IL-6 synthesis via p38 MAP kinase in osteoblasts.
[So] Source:PLoS One;12(5):e0177878, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Heat shock protein 90 (HSP90) that is ubiquitously expressed in various tissues, is recognized to be a major molecular chaperone. We have previously reported that prostaglandin F2α (PGF2α), a potent bone remodeling mediator, stimulates the synthesis of interleukin-6 (IL-6) through p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase in osteoblast-like MC3T3-E1 cells, and that Rho-kinase acts at a point upstream of p38 MAP kinase. In the present study, we investigated the involvement of HSP90 in the PGF2α-stimulated IL-6 synthesis and the underlying mechanism in MC3T3-E1 cells. Geldanamycin, an inhibitor of HSP90, significantly amplified both the PGF2α-stimulated IL-6 release and the mRNA expression levels. In addition, other HSP90 inhibitors, 17-allylamino-17demethoxy-geldanamycin (17-AAG) and 17-dimethylamino-ethylamino-17-demethoxy-geldanamycin (17-DMAG) and onalespib, enhanced the PGF2α-stimulated IL-6 release. Geldanamycin, 17-AAG and onalespib markedly strengthened the PGF2α-induced phosphorylation of p38 MAP kinase. Geldanamycin and 17-AAG did not affect the PGF2α-induced phosphorylation of p44/p42 MAP kinase and myosin phosphatase targeting subunit (MYPT-1), a substrate of Rho-kinase, and the protein levels of RhoA and Rho-kinase. In addition, HSP90-siRNA enhanced the PGF2α-induced phosphorylation of p38 MAP kinase. Furthermore, SB203580, an inhibitor of p38 MAP kinase, significantly suppressed the amplification by geldanamycin, 17-AAG or 17-DMAG of the PGF2α-stimulated IL-6 release. Our results strongly suggest that HSP90 negatively regulates the PGF2α-stimulated IL-6 synthesis in osteoblasts, and that the effect of HSP90 is exerted through regulating p38 MAP kinase activation.
[Mh] Termos MeSH primário: Benzoquinonas/farmacologia
Dinoprosta/farmacologia
Proteínas de Choque Térmico HSP90/antagonistas & inibidores
Interleucina-6/biossíntese
Lactamas Macrocíclicas/farmacologia
Osteoblastos/metabolismo
Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
[Mh] Termos MeSH secundário: Abortivos não Esteroides/farmacologia
Animais
Células Cultivadas
Regulação da Expressão Gênica/efeitos dos fármacos
Interleucina-6/genética
Camundongos
Osteoblastos/citologia
Osteoblastos/efeitos dos fármacos
Fosforilação/efeitos dos fármacos
Proteínas Quinases p38 Ativadas por Mitógeno/genética
Quinases Associadas a rho/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Abortifacient Agents, Nonsteroidal); 0 (Benzoquinones); 0 (HSP90 Heat-Shock Proteins); 0 (Interleukin-6); 0 (Lactams, Macrocyclic); 001L2FE0M3 (17-(dimethylaminoethylamino)-17-demethoxygeldanamycin); B7IN85G1HY (Dinoprost); EC 2.7.11.1 (rho-Associated Kinases); EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170526
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0177878



página 1 de 1081 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde